The immunologic balance: three cases of rituximab-associated melanoma

Tara M. Davidson, Svetomir N. Markovic, Anastasios Dimou

Research output: Contribution to journalArticlepeer-review


Currently, there is no known clinical evidence that rituximab increases the rate of subsequent primary malignancies; however, some studies have raised the question of increased melanoma risk following rituximab treatment for non-Hodgkin lymphoma. We report three interesting cases of suspected rituximab-induced melanoma. We hypothesize that this association is secondary to rituximab-driven shifts in the immunologic balance. Based on these cases, it is possible that the number of post-rituximab melanoma cases is underreported. Further mechanistic research into individual cases and population-level studies are required to better define association and risk; however, given the increasing prevalence of oncologic and nononcologic rituximab use, awareness across all fields is essential.

Original languageEnglish (US)
Pages (from-to)67-70
Number of pages4
JournalMelanoma research
Issue number1
StatePublished - Feb 1 2022


  • CD20
  • immune checkpoint
  • lymphoma
  • melanoma
  • rituximab

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research


Dive into the research topics of 'The immunologic balance: three cases of rituximab-associated melanoma'. Together they form a unique fingerprint.

Cite this